Probi AB (publ) (PROB.ST)
SEK 347.0
(-0.29%)
SEK 347.0
(-0.29%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 208.93 Million SEK | 1.98% |
| 2022 | 204.87 Million SEK | 14.6% |
| 2021 | 178.76 Million SEK | -4.03% |
| 2020 | 186.27 Million SEK | 3.43% |
| 2019 | 180.1 Million SEK | 1.8% |
| 2018 | 176.91 Million SEK | 1.77% |
| 2017 | 173.83 Million SEK | 17.47% |
| 2016 | 147.98 Million SEK | 56.78% |
| 2015 | 94.39 Million SEK | 44.58% |
| 2014 | 65.28 Million SEK | 9.51% |
| 2013 | 59.61 Million SEK | -7.86% |
| 2012 | 64.7 Million SEK | 8.3% |
| 2011 | 59.74 Million SEK | 13.97% |
| 2010 | 52.42 Million SEK | 12.59% |
| 2009 | 46.56 Million SEK | -19.11% |
| 2008 | 57.56 Million SEK | 56.37% |
| 2007 | 36.81 Million SEK | -10.79% |
| 2006 | 41.26 Million SEK | 16.0% |
| 2005 | 35.57 Million SEK | -8.17% |
| 2004 | 38.73 Million SEK | 10.41% |
| 2003 | 35.08 Million SEK | -1.79% |
| 2002 | 35.72 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 46.05 Million SEK | -14.19% |
| 2024 Q1 | 51.65 Million SEK | -5.36% |
| 2024 Q2 | 53.66 Million SEK | 3.89% |
| 2023 Q3 | 47.24 Million SEK | -18.1% |
| 2023 Q2 | 57.68 Million SEK | 16.71% |
| 2023 Q4 | 54.58 Million SEK | 15.54% |
| 2023 Q1 | 49.42 Million SEK | -18.45% |
| 2023 FY | 208.93 Million SEK | 1.98% |
| 2022 Q3 | 44.38 Million SEK | -15.4% |
| 2022 Q2 | 52.46 Million SEK | 10.67% |
| 2022 FY | 204.87 Million SEK | 14.6% |
| 2022 Q4 | 60.6 Million SEK | 36.54% |
| 2022 Q1 | 47.41 Million SEK | -2.26% |
| 2021 Q4 | 48.5 Million SEK | 13.79% |
| 2021 Q1 | 44.21 Million SEK | -9.17% |
| 2021 Q2 | 43.42 Million SEK | -1.79% |
| 2021 Q3 | 42.62 Million SEK | -1.83% |
| 2021 FY | 178.76 Million SEK | -4.03% |
| 2020 Q3 | 44.87 Million SEK | 6.56% |
| 2020 Q2 | 42.1 Million SEK | -16.82% |
| 2020 FY | 186.27 Million SEK | 3.43% |
| 2020 Q1 | 50.62 Million SEK | 14.05% |
| 2020 Q4 | 48.67 Million SEK | 8.48% |
| 2019 Q2 | 50.7 Million SEK | 8.41% |
| 2019 Q1 | 46.76 Million SEK | 3.53% |
| 2019 Q3 | 38.25 Million SEK | -24.56% |
| 2019 Q4 | 44.38 Million SEK | 16.04% |
| 2019 FY | 180.1 Million SEK | 1.8% |
| 2018 Q3 | 42.19 Million SEK | -3.69% |
| 2018 Q1 | 45.72 Million SEK | 10.59% |
| 2018 FY | 176.91 Million SEK | 1.77% |
| 2018 Q4 | 45.17 Million SEK | 7.05% |
| 2018 Q2 | 43.81 Million SEK | -4.18% |
| 2017 Q3 | 39.78 Million SEK | -13.69% |
| 2017 Q2 | 46.09 Million SEK | 12.91% |
| 2017 Q1 | 40.82 Million SEK | -23.88% |
| 2017 Q4 | 41.35 Million SEK | 3.93% |
| 2017 FY | 173.83 Million SEK | 17.47% |
| 2016 Q3 | 33.58 Million SEK | 3.06% |
| 2016 Q1 | 28.17 Million SEK | 17.85% |
| 2016 FY | 147.98 Million SEK | 56.78% |
| 2016 Q4 | 53.63 Million SEK | 59.68% |
| 2016 Q2 | 32.58 Million SEK | 15.65% |
| 2015 Q3 | 22.01 Million SEK | -16.77% |
| 2015 Q2 | 26.44 Million SEK | 20.09% |
| 2015 Q4 | 23.91 Million SEK | 8.63% |
| 2015 FY | 94.39 Million SEK | 44.58% |
| 2015 Q1 | 22.02 Million SEK | 26.79% |
| 2014 Q4 | 17.36 Million SEK | 7.24% |
| 2014 FY | 65.28 Million SEK | 9.51% |
| 2014 Q3 | 16.19 Million SEK | -5.25% |
| 2014 Q2 | 17.09 Million SEK | 16.86% |
| 2014 Q1 | 14.62 Million SEK | -5.4% |
| 2013 Q2 | 15.88 Million SEK | 14.68% |
| 2013 Q1 | 13.85 Million SEK | -19.66% |
| 2013 FY | 59.61 Million SEK | -7.86% |
| 2013 Q4 | 15.46 Million SEK | 7.29% |
| 2013 Q3 | 14.41 Million SEK | -9.3% |
| 2012 Q3 | 13.21 Million SEK | -24.08% |
| 2012 FY | 64.7 Million SEK | 8.3% |
| 2012 Q1 | 16.54 Million SEK | -9.92% |
| 2012 Q2 | 17.4 Million SEK | 5.19% |
| 2012 Q4 | 17.24 Million SEK | 30.48% |
| 2011 Q2 | 13.81 Million SEK | -19.77% |
| 2011 Q3 | 12.28 Million SEK | -11.09% |
| 2011 Q4 | 18.37 Million SEK | 49.56% |
| 2011 FY | 59.74 Million SEK | 13.97% |
| 2011 Q1 | 17.22 Million SEK | 26.1% |
| 2010 Q1 | 12.77 Million SEK | 0.0% |
| 2010 FY | 52.42 Million SEK | 12.59% |
| 2010 Q3 | 15.32 Million SEK | 29.67% |
| 2010 Q4 | 13.65 Million SEK | -10.9% |
| 2010 Q2 | 11.82 Million SEK | -7.48% |
| 2009 FY | 46.56 Million SEK | -19.11% |
| 2008 FY | 57.56 Million SEK | 56.37% |
| 2007 FY | 36.81 Million SEK | -10.79% |
| 2006 FY | 41.26 Million SEK | 16.0% |
| 2005 FY | 35.57 Million SEK | -8.17% |
| 2004 FY | 38.73 Million SEK | 10.41% |
| 2003 FY | 35.08 Million SEK | -1.79% |
| 2002 FY | 35.72 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | -1476.972% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | -446.059% |
| BioGaia AB (publ) | 507.08 Million SEK | 58.797% |
| Enzymatica AB (publ) | 79.92 Million SEK | -161.411% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | -446.573% |
| Gabather AB (publ) | 9.47 Million SEK | -2105.33% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | -1303.742% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | -660.78% |
| Nanexa AB (publ) | 135.78 Million SEK | -53.874% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | -593.876% |
| ODI Pharma AB | -5.00 SEK | 4178660100.0% |
| Orexo AB (publ) | 659.4 Million SEK | 68.315% |
| Swedencare AB (publ) | 1.12 Billion SEK | 81.474% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 97.777% |
| Toleranzia AB | 6.97 Million SEK | -2896.744% |
| Vivesto AB | 355.71 Million SEK | 41.264% |